ClinicalTrials.gg
RecruitingNCT07442188Updated Jun 3, 2026

Comparison of Postoperative Analgesic Effects of Quadro-iliac Plane Block and Transversus Abdominis Plane Blocks in Inguinal Hernia Surgery

An interventional study of TAPB and QIPB in Peripheral Nerve Block, Pain Management and Hernia, Inguinal, sponsored by Ankara Etlik City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Hernia, Inguinal with a site in Turkey — 12 open to participants now, 14 under way, none of them phase 3. Hernia, Inguinal · Turkey.

Planned enrollment
38th of 60
60 · median 80
Started
2026
with 8 others
No phase
52 of 77
11 open now
Primary completion
2026-10
later than 8 of 13 live
Registered
67th of 77
by date

Among the 77 studies in Hernia, Inguinal with a site in Turkey, this one is the 38th largest by planned enrollment of the 60 interventional ones that give a count, is one of 9 that started in 2026, is one of 52 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 67th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

12 of the 77 studies in Hernia, Inguinal with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hernia, Inguinal with a site in Turkey, or all of them as a file.
02

Study summary

Inguinal hernia repair is one of the most commonly performed surgical procedures worldwide. Despite being classified as a minor surgical intervention, moderate to severe postoperative pain is reported in approximately 60% of patients. In a subset of these patients, acute postoperative pain may persist and evolve into chronic post-surgical inguinal pain, significantly affecting quality of life.

In recent years, beyond the use of systemic intravenous analgesics, ultrasound-guided fascial plane blocks have been increasingly incorporated into multimodal analgesia protocols with the aim of reducing postoperative opioid consumption and improving pain control. However, the current literature does not provide definitive evidence regarding the superiority of one block technique over another in this surgical population.

The primary objective of the present study is to compare the analgesic efficacy of the Quadro-iliac Plane Block (QIPB) and the transversus abdominis plane block (TAPB) in patients undergoing inguinal hernia repair.

03

Conditions studied

  • Peripheral Nerve Block
  • Pain Management
  • Hernia, Inguinal

Browse trials for

Keywords

  • Quadro Iliac Plane Block
  • Transversus Abdominis Plane Block
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 65 years
  • Patients with an (ASA) physical status classification of I-III.
  • Patients with a (BMI) between 18 and 30 kg/m².
  • Patients scheduled to undergo unilateral inguinal hernia repair under general anesthesia in the operating room.

Exclusion criteria

Exclusion Criteria:

  • Patients younger than 18 years or older than 65 years.
  • Patients with an classification of IV or higher.
  • Patients with advanced comorbidities.
  • Patients with a history of bleeding diathesis.
  • Patients with infection at the site of the planned procedure.
  • Patients with a below 18 kg/m² or above 30 kg/m².
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    TAPB

    After the patients were placed under observation, positioned in the supine position, and appropriate area sterilization was performed, TAPB was administered to the patients with 30 ml of 0.25% bupivacaine under ultrasound guidance.

    Procedure: TAPB

  • Active comparator
    QIPB

    After the patients were placed under observation, positioned in the lateral decubitus position, and appropriate area sterilization was performed, QIPB was administered to the patients with 30 ml of 0.25% bupivacaine under ultrasound guidance.

    Procedure: QIPB

Interventions

  • ProcedureTAPB

    Patients will undergo TAPB procedure using 30 ml of 0.25% bupivacaine under ultrasound guidance.

  • ProcedureQIPB

    Patients will undergo QIPB procedure using 30 ml of 0.25% bupivacaine under ultrasound guidance.

06

What researchers measure

Primary outcomes

  1. Pain Score

    Pain will be assessed using a visual analog scale from 0 mm (no pain) to 100 mm (worst pain) at rest and when coughing. Pain assessment will be made at 0, 1, 6, 12, 18, and 24 hours after surgery.

    Time frame: Up to 24 hours

Secondary outcomes

  1. Patient Satisfaction

    Quality of recovery-15 (QoR-15) score was used as the satisfaction score. The patient-reported Turkish QoR-15 score includes 15 questions that evaluate the patient's postoperative recovery. The QoR-15 score is grouped under two groups, A and B. A high QoR-15 score, a score between 0 (poor) and 10 (excellent) for each item, and a total score of 150 indicate better quality of recovery.

    Time frame: 24th hour

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.

Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 4 months is below that.

Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Oct 5, 2026
CompletionEst.
Oct 19, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07442188
Responsible party
İbrahim Topcu (Principal Investigator, Ankara Etlik City Hospital) — Principal investigator
First posted
Mar 2, 2026
Start date
Jun 2, 2026
Primary completion
Oct 5, 2026 (estimated)
Completion
Oct 19, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Ibrahim Topcu, MD
Contact
ibrahimtpc78@gmail.com
+905437860316
Musa Zengin, Associate Professor
Contact
musazengin@gmail.com
+905307716235

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion